Circulating CD14+ monocytes in patients with aortic stenosis

Sara Shimoni, Valery Meledin, Iris Bar, Jacob Fabricant, Gera Gandelman, Jacob George
Heart Institute, Kaplan Medical Center; Rehovot, Israel

Abstract

Background Calcific aortic stenosis (AS) is an active process sharing similarities with atherosclerosis and chronic inflammation. The pathophysiology of AS is notable for three cardinal components: inflammation, fibrosis and calcification. Monocytes play a role in each of these processes. The role of circulating monocytes in AS is not clear. The aim of the present study was to study an association between circulating apoptotic and non apoptotic CD14+ monocytes and AS features. Methods We assessed the number of CD14+ monocytes and apoptotic monocytes in 54 patients with significant AS (aortic valve area 0.74 ± 0.27 cm2) and compared them to 33 patients with similar risk factors and no valvular disease. The level of CD14+ monocytes and apoptotic monocytes was assessed by flow cytometry. Results There was no difference in the risk factor profile and known coronary or peripheral vascular diseases between patients with AS and controls. Patients with AS exhibited increased numbers of CD14+ monocytes as compared to controls (9.9% ± 4.9% vs. 7.7% ± 3.9%, P = 0.03). CD14+ monocyte number was related to age and the presence and severity of AS. In patients with AS, both CD14+ monocytes and apoptotic monocytes were inversely related to aortic valve area. Conclusions Patients with significant AS have increased number of circulating CD14+ monocytes and there is an inverse correlation between monocyte count and aortic valve area. These findings may suggest that inflammation is operative not only in early valve injury phase, but also at later developed stages such as calcification when AS is severe.

Keywords: Aortic stenosis; Inflammation; Monocytes

1 Introduction

Degenerative aortic stenosis (AS) is the most common valvular disease and increases in prevalence with age. [1] Severe AS accounts for considerable morbidity and death, especially in older patients. Aortic valve stenosis is the primary indication for valve replacement in Western countries, and the number continues to increase as the population grows older. The treatment of elderly patients with severe AS is difficult. Compared to younger groups, elderly patients have increased risk. Calcific AS is an active process sharing similarities with atherosclerosis with lipoprotein deposition, chronic inflammation, and active leaflet calcification. As in atherosclerosis, the histological findings seen at different stages of the disease include presence of macrophages, foam cells, T lymphocytes, lipoproteins, heterotrophic calcification, and bone tissue. [2–4] The monocyte is considered a key cellular player in atherogenesis and its transition to macrophage is a requisite to the initial and subsequent stages of the process. [5] Moreover, monocytes are the most abundant immune cell type in atherosclerotic plaques and are the central drivers of vascular inflammation in atherosclerosis. [6,7] Circulating CD14CD16+ monocytes were shown to be related to atherosclerosis and coronary artery disease severity, as well as progression. [6,9] Although, monocyte apoptosis is suggestive to be protective in atheromas, monocyte derived microparticles promote atherogenesis. [10] Inflammatory cells are the predominant cell type in early aortic valve lesions. Inflammatory infiltration of activated macrophages and T-cells, as well as cytokine release has been reported in stenotic aortic valves, [4,11,12] and enhanced levels of mRNA of inflammatory leukotriene pathway enzymes are found in thickened stenotic aortic valves and correlate with stenosis severity. [13] Monocytes infiltrate endothelial layer via adhesion molecules and differentiate into macrophages. Macrophages express osteopontin, which is related to valvular calcification. [2,11,12,14–16] The role of circulating CD14+ monocytes in AS is not clear. We designed our study to assess an association between circulating CD14+ monocyte levels, subsets of apoptotic monocytes and features of AS.

2 Methods

Fifty four consecutive patients with significant AS (10...
with moderate and 44 with severe AS) and a control group of 33 patients were enrolled in study. Patients who had significant valvular disease other than AS or those who underwent aortic valve replacement or percutaneous balloon valvuloplasty were excluded. Functional class was assessed according to NYHA classification. The study was approved by the institutional ethics committee and all patients provided written informed consent.

2.1 Assessment of risk factors

Risk factors were assessed in all patients based on medical records. We defined diabetes mellitus as hyperglycemia requiring pharmacologic therapy; hypertension as either a systolic or diastolic increase in blood pressure (>140/90 mmHg) or use of antihypertensive therapy; hypercholesterolemia as a total cholesterol level of greater than 200 mg/dL or use of lipid-lowering agents; and cigarette smoking as being an active smoker or having a smoking history of at least 10 pack-years. Coronary artery disease (CAD) was defined as a history of myocardial infarction or presence of CAD on coronary angiography. Peripheral vascular disease (PVD) was defined as history of intermittent claudication or presence of PVD on peripheral angiography.

2.2 Transthoracic echocardiography

Transthoracic echocardiography including assessment of the aortic valve was performed according to established guidelines. Standard M-mode, 2-dimensional, continuous wave Doppler of the aortic, mitral and tricuspid flow as well as pulsed-wave Doppler examination of left ventricular outflow tract and mitral inflow were performed in each subject. Left ventricle dimensions, left atria area, aortic root and ascending aorta diameter were assessed. Grade of diastolic dysfunction, pulmonary pressure and left ventricular mass were calculated. Left ventricular ejection fraction (LVEF) was visually estimated by experienced independent operators. Aortic valve was assessed in short and long-axis echocardiographic views. Maximal velocity, maximal and mean flow were performed in each subject. Left ventricle dimensions, left atria area, aortic root and ascending aorta diameter were assessed. Grade of diastolic dysfunction, pulmonary pressure and left ventricular mass were calculated. Left ventricular ejection fraction (LVEF) was visually estimated by experienced independent operators. Aortic valve was assessed in short and long-axis echocardiographic views. Maximal velocity, maximal and mean flow were performed in each subject.

2.3 Quantification of CD14+ monocytes by flow cytometry

Peripheral blood was drawn from patients with AS and control donors. The number of monocytes (defined as CD14+ cells) was quantified by flow cytometry. 7.5 × 10⁶ mononuclear cells (MNCs) were isolated from peripheral blood by density gradient centrifugation, and were incubated at 4°C in the dark for 30 min with mouse anti-human CD14-PE and its isotope control (bioscience, San Diego, USA). After incubation, cells were washed with phosphate buffered saline (PBS), and analyzed by FACS (LSRII, Becton Dickinson). For a clear analysis, at least 50,000 total events or 1000 CD14+ events were collected by flow cytometry.

2.4 Flow cytometry evaluation of early and late apoptotic CD14+ monocytes

Apoptosis of CD14+ monocyte was assessed using Southern Biotech Apo Screen Annexin V apoptosis detection kit (Annexin V-FITC, 7-AAD solution and Annexin V binding buffer). This assay involves staining peripheral blood mononuclear cells with Annexin V-FITC (a phospholipid-binding protein binding to disrupted cell membranes) in combination with 7-AAD (a vital dye binding to DNA penetrating into apoptotic cells). Fluorescence-activated cell sorting (FACS) analysis of CD14+ monocytes that are in early (annexin V+/7-AAD−) or late (annexin V+/7-AAD+) apoptotic phase was performed. The percentage of apoptotic CD14+ monocytes (out of total circulating CD14+ cells) was assessed by staining peripheral blood mononuclear cells for 3 color FACS analysis employing anti-CD14-PE (eBioscience), Annexin V-FITC and 7-AAD (SouthernBiotech). The cells were then washed again with PBS and re-suspended in 100 μL Annexin V-FITC binding buffer and incubated with 5 μL of Annexin V- FITC for 15 min at room temperature. Another 200 μL of binding buffer and 5 μL of 7-AAD solution were added without washing, and 100,000 cells were acquired by flow cytometry (FACS Calibur, Becton Dickinson) and analyzed by CellQuest software (BD Bioscience). All analyses and readings were made by researchers who were blinded to the study questions.

2.5 Statistical analysis

Continuous data are presented as medians and interquartile ranges (25th–75th percentiles) for skewed distributed variables or as mean ± SD when normally distributed, and categorical data are presented as absolute numbers and respective percentages. Chi-square tests were used for categorical variables and Student’s t test for continuous variables. Student’s t test was used to compare CD14+ monocytes and apoptotic monocytes in patients with AS and control group. Regression analysis and analysis of variance for monocytes by independent variables was performed in all cases. All above analyses were considered significant at \( P \leq 0.05 \).

3 Results

The study included 54 consecutive patients with moder-
ate and severe AS who met the inclusion criteria and a control group of 33 patients with no significant valvular disease. The mean AVA was 0.74 ± 0.27 cm². The etiology of AS in all patients was degenerative disease. A control group included 33 stable patients with no valvular disease who were referred to coronary angiography for chest pain evaluation or patients with atrial arrhythmia referred to echocardiography.

Baseline characteristics and laboratory results of the patients are shown in Table 1. The patients with AS were older and predominantly female, features that have not been known to associate with circulating CD14⁺ cell levels. There was no difference in the risk factors and known coronary or peripheral vascular diseases between patients with AS and controls. The hemoglobin level was lower in patients with AS compared to patients with no AS.

There was more significant left ventricular hypertrophy in patients with AS, however there was no change in left ventricular chamber systolic and diastolic diameter and LVEF. Patients with AS had higher pulmonary artery pressure, however this difference was not statistically significant (Table 2).

As shown in Figure 1, patients with severe AS have increased number of monocytes as compared to controls (9.9% ± 4.9% vs. 7.7% ± 3.9%, P = 0.03). The absolute monocyte number was also higher in patients with AS compared to the control group (0.77 ± 0.06 × 10⁹/L vs. 0.55 ± 0.06 × 10⁹/L, P = 0.0256). There is no difference in the number of early apoptotic monocytes among the groups (P

| Table 1. Baseline characteristics of patients with AS and control group. |
|---------------------------------------------------------------|
| AS, n = 54 | Control, n = 33 | P     |
| Age, yrs | 76 ± 10 | 63 ± 12 | < 0.001 |
| Male | 36 (67%) | 12 (36%) | 0.02 |
| Hypertension | 38 (70%) | 16 (48%) | 0.07 |
| Diabetes mellitus | 19 (35%) | 10 (30%) | 0.43 |
| Hypercholesterolemia | 37 (69%) | 24 (72%) | 0.86 |
| Smoking | 5 (9%) | 3 (9%) | 0.9 |
| CAD/PVD | 25 (46%) | 10 (30%) | 0.2 |
| Aspirin therapy | 37 (68%) | 14 (42%) | 0.32 |
| Statin therapy | 34 (72%) | 17 (50%) | 0.6 |
| β-lockers | 25 (46%) | 12 (35%) | 0.98 |
| ACEI | 29 (64%) | 11 (33%) | 0.68 |
| Hg, g/dL | 11.4 ± 2.4 | 13.8 ± 1.5 | 0.006 |
| WBC × 10⁹/µL | 7.4 ± 2.4 | 7.5 ± 1.5 | 0.19 |
| Platelets × 10⁹/µL | 246 ± 144 | 208 ± 59 | 0.52 |
| Creatinine, mg/dL | 0.94 ± 0.4 | 0.87 ± 0.2 | 0.18 |
| Total cholesterol, mg/dL | 166 ± 40 | 179 ± 40 | 0.26 |
| LDL cholesterol, mg/dL | 88 ± 36 | 104 ± 36 | 0.32 |
| Triglycerides, mg/dL | 123 ± 59 | 126 ± 52 | 0.91 |
| HDL cholesterol, mg/dL | 47 ± 15 | 52 ± 11 | 0.57 |

Data are presented as n (%) or mean ± SD. ACEI: angiotensin converting enzyme inhibitor; AS: aortic stenosis; CAD: coronary artery disease; HDL: high density cholesterol; Hg: haemoglobin; LDL: low density cholesterol; PVD: peripheral artery disease; WBC: white blood cells.

| Table 2. Echocardiographic data in patients with moderate and severe AS and control group. |
|---------------------------------------------------------------|
| AS, n = 54 | Control, n = 33 | P     |
| LVDD, mm | 45.1 ± 6 | 46.5 ± 6 | 0.4 |
| LVSD, mm | 28.1 ± 7 | 27 ± 6 | 0.75 |
| Septal thickness, mm | 13.9 ± 1.8 | 12.5 ± 2.7 | 0.04 |
| Posterior wall thickness, mm | 12.5 ± 1.9 | 11.3 ± 1.5 | 0.02 |
| LVEF, % | 56.2 ± 6.7 | 56.9 ± 5.6 | 0.68 |
| Aortic root diameter, mm | 30 ± 4 | 32.7 ± 3.1 | 0.19 |
| Ascending aorta diameter, mm | 33 ± 6 | 32.8 ± 2 | 0.6 |
| Left atrial area, cm² | 24.9 ± 6 | 22.3 ± 4 | 0.18 |
| AVA, cm² | 0.74 ± 0.27 | Peak AV gradient, mmHg | 75.8 ± 34 |
| Mean AV gradient, mmHg | 49.2 ± 22 | Pulmonary artery pressure, mmHg | 43.9 ± 13 | 35 ± 4 | 0.073 |

Data are presented as mean ± SD. AS: aortic stenosis; AV: aortic valve; AVA: aortic valve area; LVDD: left ventricular end diastolic diameter; LVEF: left ventricular ejection fraction; LVSD: left ventricular end systolic diameter.
= 0.24, Figure 2). A representative flow cytometric evaluation of CD14+ monocytes and relative number of apoptotic CD14+ cells in a patient with severe AS and without AS is shown in Figure 3.

We tested the association between monocytes and various clinical and echocardiographic parameters in patients with AS and controls. CD14+ monocyte number was related to age, the morphology of the aortic valve and the presence of AS only. There was no correlation between NYHA class and monocyte levels (P = 0.86). The number of monocytes was similar in patients with and without coronary artery disease (P = 0.77). Using backward stepwise regression analysis, AS was found to be the only predictor for CD14+ monocytes levels in the entire study population (P = 0.03). CD14+ early apoptotic monocytes, however, were associated with age only (P = 0.02).

We also tested the correlation between CD14+ monocytes and apoptotic monocytes and various clinical and echocardiographic parameters in patients with AS only. There was no correlation between monocytes or apoptotic monocytes and LVEF (P = 0.61 and P = 0.57, respectively). In patients with AS both CD14+ monocytes and apoptotic monocytes correlated negatively with AVA only (Figure 4).

4 Discussion

In the present study, we have shown an increased number of circulating CD14+ monocytes in patients with significant senile AS. Also, we have found an inverse correlation between monocyte count and aortic valve area. There was no difference in the number of apoptotic CD14+ monocytes between patients with AS and controls; however apoptotic monocytes correlated with aortic valve area.

An inflammatory basis for AS is supported by studies demonstrating increased C-reactive protein concentrations in patients with AS,[18] and increased temperature in stenotic aortic valve cusps.[19] Recently, 18F fluorodeoxyglucose uptake has been shown to be increased in patients with AS compared with controls, displaying a progressive rise in activity with increasing valve severity.[20,21] AS pathophysi-
Figure 4. The correlation between CD14⁺ (A) and apoptotic CD14⁺ (B) monocytes and AVA in patients with aortic stenosis.

AVA: aortic valve area.

Monocytes in aortic stenosis

Shimoni S, et al. Monocytes in aortic stenosis

The presence of large number of monocyte/macrophages in the stenotic valves suggests that circulating monocytes contribute to aortic valve calcification and stenosis. The primary function of circulating monocytes is non-specific host protection against foreign pathogens via their prompt elimination (innate immunity). However, the ‘dark’ side of the process is the damage of the host’s own tissues. Circulating monocytes derive from hematopoietic precursor cells in the bone-marrow and are mobilized into the circulation and thence to the vascular wall by biological stimulants abundantly produced by damaged tissues. Since the vascular and valvular walls are located in direct proximity to the circulation, they are especially vulnerable to the effect of the circulating monocytes.

In our previous study, we evaluated the association between the averages of repeated white blood cells differential counts sampled during the previous three years and subsequent echocardiographic AS indices. We found that severe AS was associated with decreased total monocyte count during the previous three years. The present findings do not support this observation. On the contrary, we found for calcification, elevated levels of adhesion molecules, T lymphocytes, and monocytes are present in calcified valves, suggesting that an inflammatory infiltrate is necessary for lesion formation and progression. Animal models of heterotopic bone formation demonstrate that inflammatory signals are necessary to trigger distant ossification in a bone morphogenetic proteins conducive environment. In one of these models, cells of the monocyte lineage were required for initiating extra skeletal bone following injury. Fadini and colleagues reported mineralization potential in cells of hematopoietic origin: circulating myeloid cells that produce calcium mineral when cultured in a solubilized basement membrane matrix derived from mouse sarcoma cells. These circulating cells also express monocyte/macrophage lineage markers (CD45, CD14, and CD68), as well as the osteoblastic markers alkaline phosphatase (BAP, also known as tissue-nonspecific alkaline phosphatase), osteocalcin and the osteochondrogenic transcription factors Runx2 and osteoterix. Egan, et al. found that circulating osteogenic cells home to sites of valvular injury and are intimately associated with bone formation. Circulating osteogenic precursors (COP) cells, as well as monocyte-derived mesenchymal progenitors, are derived from CD14 precursors and can be induced to differentiate into osteoblast-like cells. Diehl, et al. found that patients with severe AS had increased numbers of CD11b⁺ activated monocyte cells in their blood compared with controls and also had higher numbers of platelet microparticles conjugated to monocytes compared to controls.

The presence of large number of monocyte/macrophages in the stenotic valves suggests that circulating monocytes contribute to aortic valve calcification and stenosis. The primary function of circulating monocytes is non-specific host protection against foreign pathogens via their prompt elimination (innate immunity). However, the ‘dark’ side of the process is the damage of the host’s own tissues. Circulating monocytes derive from hematopoietic precursor cells in the bone-marrow and are mobilized into the circulation and thence to the vascular wall by biological stimulants abundantly produced by damaged tissues. Since the vascular and valvular walls are located in direct proximity to the circulation, they are especially vulnerable to the effect of the circulating monocytes.

In our previous study, we evaluated the association between the averages of repeated white blood cells differential counts sampled during the previous three years and subsequent echocardiographic AS indices. We found that severe AS was associated with decreased total monocyte count during the previous three years. The present findings do not support this observation. On the contrary, we found

http://www.jgc301.com; jgc@mail.sciencep.com | Journal of Geriatric Cardiology
increased number of CD14+ monocytes in patients with significant AS. However, we believe that there is no true contradiction in results since the monocyte count assessment in our previous study was done by automatic blood analyzers that have disadvantages of relating to a highly heterogeneous population of mononuclear cells.

Activated monocytes appear to be resistant to apoptosis and apoptotic monocytes have been shown to be related to better prognosis in sepsis. However, micro-particles of apoptotic monocytes were shown to have procoagulative and proatherosclerotic effect. We did not find difference in the number of CD14+ apoptotic monocytes in patients with AS as compared to controls. However in patients with AS, a negative correlation was found between apoptotic CD14+ monocytes and AVA. We cannot infer whether this finding suggest causality or that the higher number of apoptotic monocytes and more severe AS is due to the hemodynamic changes seen in these patients.

Our study is limited by a relatively small study population. AS is a relatively common valvular disease however the number of patients is significantly smaller than those with coronary atherosclerotic disease. The control group was patients with no AS. A larger scale study is needed to compare patients with various stages of AS and aortic sclerosis. We looked on CD14+ and did not assess monocyte sub populations. Future studies may need to identify cellular subsets and role in AS. The patients with AS were older compared to the control group and there were more female in this group. However, the difference in the monocyte levels between patients with AS and the control group remained significant after correcting for this factors. Circulating CD14+ monocytes do not change significantly with age.[36] In elderly patients with chronic disease, the number of CD14+ monocytes may even decrease, supporting our results that the increase in circulating CD14+ is related to AS.[17]

We found, similar to the reports on circulating monocytes in atherosclerosis, a correlation between circulating monocytes and AS severity. The significance and relevance of measuring circulation monocytes and apoptotic monocytes in patients with AS is not clear and needs to be further evaluated.

Higher percent of CD14+ monocytes in patients with significant AS may represent a marker of disease severity, reflecting increased mobilization of leukocytes. However, it is possible that circulating monocytes are involved in the inflammatory process of AS. Further studies are needed to assess the involvement of monocytes in AS progression; this may also focus attention to novel measures to treat this disease by modulating monocytes.

Acknowledgement

All authors take responsibility for all aspects of the reliability and freedom from bias of the data presented and their discussed interpretation. There is no conflict of interest.

References

1. Iung B, Baron G, Butchart EG, et al. A prospective survey of patients with valvular heart disease in Europe: The Euro Heart Survey on Valvular Heart Disease. Eur Heart J 2003; 24: 1231–1243.
2. Otto CM, Kuusisto J, Reichenbach DD, et al. Characterization of the early lesion of ‘degenerative’ valvular aortic stenosis. Histological and immunohistochemical studies. Circulation 1994; 90: 844–853.
3. Mazzone A, Epistolato MC, Gianetti J, et al. Biological features (inflammation and neoangiogenesis) and atherosclerotic risk factors in carotid plaques and calcified aortic valve stenosis: two different sites of the same disease? Am J Clin Pathol 2006; 126: 494–502.
4. Helske S, Kupari M, Lindstedt KA, et al. Aortic valve stenosis: an active atheroinflammatory process. Curr Opin Lipidol 2007; 18: 483–491.
5. Woollard KJ, Geissmann F. Monocytes in atherosclerosis: subsets and functions. Nat Rev Cardioil 2010; 7: 77–86.
6. Weber C, Noels H. Atherosclerosis: current pathogenesis and therapeutic options. Nat Med 2011; 17: 1410–1422.
7. Martinovic I, Abegunewardene N, Seul M, et al. Elevated monocyte chemoattractant protein-1 serum levels in patients at risk for coronary artery disease. Circ J 2005; 69: 1484–1489.
8. Rogacev KS, Cremers B, Zawada AM, et al. CD14+CD16+ monocytes independently predict cardiovascular events: a cohort study of 951 patients referred for elective coronary angiography. J Am Coll Cardiol 2012; 60: 1512–1520.
9. Ozaki Y, Imanishi T, Taruya A, et al. Circulating CD14+CD16+ monocyte subsets as biomarkers of the severity of coronary artery disease in patients with stable angina pectoris. Circ J 2012; 76: 2412–2418.
10. Hoyer FF, Giesen MK, Nunes Franca C, et al. Monocytic microparticles promote atherogenesis by modulating inflammatory cells in mice. J Cell Mol Med 2012; 16: 2777–2788.
11. Rajamannan NM, Subramaniam M, Rickard D, et al. Human aortic valve calcification is associated with an osteoblast phenotype. Circulation 2003; 107: 2181–2184.
12. Mohler ER, 3rd, Gannon F, Reynolds C, et al. Bone formation and inflammation in cardiac valves. Circulation 2001; 103: 1522–1528.
13. Nagy E, Andersson DC, Caidahl K, et al. Upregulation of the 5-lipoxygenase pathway in human aortic valves correlates with severity of stenosis and leads to leukotriene-induced effects on valvular myofibroblasts. Circulation 2011; 123: 1316–1325.
14. Lindroos M, Kupari M, Valvanne J, et al. Factors associated
with calcific aortic valve degeneration in the elderly. *Eur Heart J* 1994; 15: 865–870.

15 Boon A, Cherix E, Lodder J, *et al.* Cardiac valve calcification: characteristics of patients with calcification of the mitral annulus or aortic valve. *Heart* 1997; 78: 472–474.

16 Stewart BF, Siscovick D, Lind BK, *et al.* Clinical factors associated with calcific aortic valve disease. Cardiovascular Health Study. *J Am Coll Cardiol* 1997; 29: 630–634.

17 Baumgartner H, Hung J, Bermejo J, *et al.* Echocardiographic assessment of valve stenosis: EAE/ASE recommendations for clinical practice. *Eur J Echocardiogr* 2009; 10: 1–25.

18 Galante A, Pietroiusti A, Vellini M, *et al.* C-reactive protein is increased in patients with degenerative aortic valvular stenosis. *J Am Coll Cardiol* 2001; 38: 1078–1082.

19 Toutouzas K, Drakopoulou M, Synetos A, *et al.* In vivo aortic valve thermal heterogeneity in patients with nonrheumatic aortic valve stenosis the: first in vivo experience in humans. *J Am Coll Cardiol* 2008; 52: 758–763.

20 Dweck MR, Jones C, Joshi NV, *et al.* Assessment of valvular calcification and inflammation by positron emission tomography in patients with aortic stenosis. *Circulation* 2012; 125: 76–86.

21 Marincheva-Savcheva G, Subramanian S, Qadir S, *et al.* Imaging of the aortic valve using fluorodeoxyglucose positron emission tomography increased valvular fluorodeoxyglucose uptake in aortic stenosis. *J Am Coll Cardiol* 2011; 57: 2507–2515.

22 Dweck MR, Boon NA, Newby DE. Calcific aortic stenosis: a disease of the valve and the myocardium. *J Am Coll Cardiol* 2012; 60: 1854–1863.

23 O’Brien KD, Reichenbach DD, Marcovina SM, *et al.* Apolipoproteins B, (a), and E accumulate in the morphologically early lesion of ‘degenerative’ valvular aortic stenosis. *Arterioscler Thromb Vasc Biol* 1996; 16: 523–532.

24 Olsson M, Thyberg J, Nilsson J. Presence of oxidized low density lipoprotein in nonrheumatic stenotic aortic valves. *Arterioscler Thromb Vasc Biol* 1999; 19: 1218–1222.

25 Parhami F, Morrow AD, Bulucan J, *et al.* Lipid oxidation products have opposite effects on calcifying vascular cell and bone cell differentiation. A possible explanation for the paradox of arterial calcification in osteoporotic patients. *Arterioscler Thromb Vasc Biol* 1997; 17: 680–687.

26 Ghaisas NK, Foley JB, O’Briain DS, *et al.* Adhesion molecules in nonrheumatic aortic valve disease: endothelial expression, serum levels and effects of valve replacement. *J Am Coll Cardiol* 2000; 36: 2257–2262.

27 Jian B, Narula N, Li QY, *et al.* Progression of aortic valve stenosis: TGF-beta1 is present in calcified aortic valve cusps and promotes aortic valve interstitial cell calcification via apoptosis. *Ann Thorac Surg* 2003; 75: 457–465; Discussion 65–66.

28 Kaden JJ, Dempfle CE, Grobholz R, *et al.* Interleukin-1 beta promotes matrix metalloproteinase expression and cell proliferation in calcific aortic valve stenosis. *Atherosclerosis* 2003; 170: 205–211.

29 Liu AC, Joag VR, Gotlieb AI. The emerging role of valve interstitial cell phenotypes in regulating heart valve pathobiology. *Am J Pathol* 2007; 171: 1407–1418.

30 Yu PB, Deng DY, Lai CS, *et al.* BMP type I receptor inhibition reduces heterotopic [corrected] ossification. *Nat Med* 2008; 14: 1363–1369.

31 Kan L, Liu Y, McGuire TL, *et al.* Dysregulation of local stem/progenitor cells as a common cellular mechanism for heterotopic ossification. *Stem Cells* 2009; 27: 150–156.

32 Fadini GP, Albiero M, Menegazzo L, *et al.* Widespread increase in myeloid calcifying cells contributes to ectopic vascular calcification in type 2 diabetes. *Circ Res* 2011; 108: 1112–1121.

33 Egan KP, Kim JH, Mohler ER 3rd, Pignolo RJ. Role for circulating osteogenic precursor cells in aortic valvular disease. *Arterioscler Thromb Vasc Biol* 2011; 31: 2965–2971.

34 Diehl P, Nagy F, Sossong V, *et al.* Increased levels of circulating microparticles in patients with severe aortic valve stenosis. Thrombosis and haemostasis 2008; 99: 711–719.

35 Schwartzenberg S, Meledin V, Zilberman L, *et al.* Low circulating monocyte count is associated with severe aortic valve stenosis. *Isr Med Assoc J* 2013; 15: 500–504.

36 Seidler S, Zimmermann HW, Bartneck M, *et al.* Age-dependent alterations of monocyte subsets and monocyte-related chemokine pathways in healthy adults. *BMC Immunology* 2010; 11: 30.

37 Verschoor CP, Johnstone J, Millar J, *et al.* Alterations to the frequency and function of peripheral blood monocytes and associations with chronic disease in the advanced-age, frail elderly. *PLoS One* 2014; 9: e104522.